Measles
Practice Essentials
Measles, also known as rubeola, is one of the most contagious infectious diseases, with at least a 90% secondary infection rate in susceptible domestic contacts. Despite being considered primarily a childhood illness, measles can affect people of all ages. See the image below.
📷Face of boy with measles.
.Although the elimination of endemic measles transmission in the US in 2000 was sustained through at least 2011, according to a CDC study, cases continue to be caused by virus brought into the country by travelers from abroad, with spread occurring largely among unvaccinated individuals. In 88% of the cases reported between 2000 and 2011, the virus originated from a country outside the US, and 2 out of every 3 individuals who developed measles were unvaccinated. Moreover, the director of the CDC noted that, in 2013, US measles cases increased threefold from the previous median, to 175 cases. [1, 2] Most of these cases were outbreaks in children whose parents had refused immunization.
This trend of increased incidence continued into 2014. From January 1 to May 23, 2014, 288 confirmed cases were reported to the CDC, a figure that exceeds the highest reported annual total number of cases (220 cases in 2011) since measles was declared eliminated in the United States in 2000. Of the 288 cases, 200 (69%) occurred in unvaccinated individuals and 58 (20%) in persons with unknown vaccination status. Nearly all of the 2014 cases reported thus far (280 [97%]) were associated with importations from at least 18 countries. Eighteen states and New York City reported measles infections during this period, and 15 outbreaks accounted for 79% of reported cases, including a large ongoing outbreak in Ohio primarily among unvaccinated Amish persons, with 138 cases reported. [3] Public health officials confirmed a total of 59 cases of measles in California residents since the end of December 2014. Of the confirmed cases, 42 have been linked to an initial exposure in December at Disneyland or Disney California Adventure Park in Anaheim, California. [4]A study by Gastañaduy et al found that during the 2014 measles outbreak, the spread of measles was contained in an undervaccinated Amish community by the isolation of case patients, quarantine of susceptible individuals, and giving the MMR vaccine to more than 10,000 people. As a result, the spread of measles was limited to about 1% in an Amish community of 32,630. [5, 6]981 cases, the highest number of cases since 1992, have been reported in 2019, Measles have been reported in 26 states from January 1 to May 31, 2019: Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Maine, Maryland, Massachusetts, Michigan, Missouri, New Mexico, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Texas, Tennessee, and Washington. [50, 51]See 11 Travel Diseases to Consider Before and After the Trip, a Critical Images slideshow, to help identify and manage several infectious travel diseases. Guidelines on measles from the American Academy of Pediatrics
The American Academy of Pediatrics released updated measles guidelines in response to the national outbreak of the disease. The new guidelines feature changes in the evidence required for measles immunity, the use of immune globulin, vaccination for healthcare personnel, and the management of patients with HIV infections and other susceptibilities. [7, 8]
Any of the following constitutes evidence of immunity to measles:
See the list below:
-Documentation of age-appropriate vaccination with a live measles virus–containing vaccine (one dose for preschool-aged children, two doses for children in kindergarten through 12th grade)
-Laboratory evidence of immunity
-Laboratory confirmation of disease
-Birth before 1957
-Use of immune globulin
See the list below: -Clinicians can administer immune globulin either intramuscularly or intravenously within 6 days of exposure to prevent or modify measles response in people who lack evidence of measles immunity. -The recommended dose is 0.50 mL/kg administered intramuscularly, with a maximum volume of 15 mL. -Groups who are at higher risk for complications from severe measles should receive intravenous application at a dose of 400 mg/kg. -People with HIV infections
See the list below: -Measles immunization (in the form of the measles, mumps, and rubella vaccine) for everyone older than 12 mo who is infected by HIV, except those who have evidence of severe immunosuppression. Measles can be fatal in patients with HIV. -Immune globulin prophylaxis for HIV-infected children who are exposed to measles, depending on their immune status and measles vaccine history. -Healthcare personnel
See the list below: Immunization programs for healthcare personnel, including students, who may be in contact with patients with measles. Birth before 1957 is not a guarantee of measles immunity; facilities should consider vaccination of unimmunized healthcare personnel who lack laboratory evidence of immunity who were born before 1957. Management of susceptible individuals
See the list below: -Clinicians can best manage immunodeficient and immunosuppressed patients exposed to measles if they have previous knowledge of the patients' immune status. -Children should receive measles vaccination prior to treatment with biological response modifiers, such as tumor necrosis factor antagonists. -Susceptible patients with immunodeficiencies should receive immune globulin after measles exposure. -Warning against giving live-virus measles vaccines to immunocompromised patients with disorders associated with increased severity of viral infections (except people with --HIV who do not have evidence of severe immunosuppression). -Recommendation not to give immunization for at least a month after a patient has finished a high-dose course of corticosteroids, such as prednisone.
Signs and symptoms Onset of measles ranges from 7-14 days (average, 10-12 days) after exposure to the virus. The first sign of measles is usually a high fever (often >104o F [40o C]) that typically lasts 4-7 days. The prodromal phase is also marked by malaise; anorexia; and the classic triad of conjunctivitis, cough, and coryza (the “3 Cs”). Other possible prodromal manifestations include photophobia, periorbital edema, and myalgias.
Enanthem Koplik spots—bluish-gray specks or “grains of sand” on a red base—develop on the buccal mucosa opposite the second molars Generally appear 1-2 days before the rash and last 3-5 days Pathognomonic for measles, but not always present
Rash On average, the rash develops about 14 days after exposure Mild pruritus may also occur Blanching, erythematous macules and papules begin on the face at the hairline, on the sides of the neck, and behind the ears Within 48 hours, the lesions coalesce into patches and plaques that spread cephalocaudally to the trunk and extremities, including the palms and soles, while beginning to regress cephalocaudally, starting from the head and neck Lesion density is greatest above the shoulders, where macular lesions may coalesce The eruption may also be petechial or ecchymotic in nature Patients appear most ill during the first or second day of the rash The exanthem lasts for 5-7 days before fading into coppery-brown hyperpigmented patches, which then desquamate Immunocompromised patients may not develop a rash
Clinical course Uncomplicated measles, from late prodrome to resolution of fever and rash, lasts 7-10 days Cough may be the final symptom to appear
Modified measles Occurs in individuals who have received serum immunoglobulin after exposure to the measles virus The incubation period may be as long as 21 days Similar but milder symptoms and signs may occur
Atypical measles Occurs in individuals who were vaccinated with the original killed-virus measles vaccine between 1963 and 1967 and who have incomplete immunity A mild or subclinical prodrome of fever, headache, abdominal pain, and myalgias precedes a rash that begins on the hands and feet and spreads centripetally The eruption is accentuated in the skin folds and may be macular, vesicular, petechial, or urticarial Diagnosis Although the diagnosis of measles is usually determined from the classic clinical picture, laboratory identification and confirmation of the diagnosis are necessary for public health and outbreak control. Laboratory confirmation is achieved by means of the following:
Serologic testing for measles-specific IgM or IgG titers Isolation of the virus Reverse-transcriptase polymerase chain reaction (RT-PCR) evaluation
Measles-specific IgM titers Obtain blood on the third day of the rash or on any subsequent day up to 1 month after onset The measles serum IgM titer remains positive 30-60 days after the illness in most individuals but may become undetectable in some subjects at 4 weeks after rash onset False-positive results can occur in patients with rheumatologic diseases, parvovirus B19 infection, or infectious mononucleosis
Measles-specific IgG titers More than a 4-fold rise in IgG antibodies between acute and convalescent sera confirms measles Acute specimens should be drawn on the seventh day after rash onset Convalescent specimens should be drawn 10-14 days after that drawn for acute serum The acute and convalescent sera should be tested simultaneously as paired sera
Viral culture Throat swabs and nasal swabs can be sent on viral transport medium or a viral culturette swab Urine specimens can be sent in a sterile container Viral genotyping in a reference laboratory may determine whether an isolate is endemic or imported In immunocompromised patients, isolation of the virus or identification of measles antigen by immunofluorescence may be the only feasible method of confirming the diagnosis
Polymerase chain reaction RT-PCR, if available, can rapidly confirm the diagnosis of measles [9] Blood, throat, nasopharyngeal, or urine specimens can be used Samples should be collected at the first contact with a suspected case of measles
Case reporting Immediately reporting any suspected case of measles to a local or state health department is imperative. The US CDC clinical case definition for reporting purposes requires only the following: Generalized rash lasting 3 days or longer Temperature of 101.0°F (38.3°C) or higher Cough, coryza, or conjunctivitis
For reporting purposes for the CDC, cases are classified as follows: Suspected: Any febrile illness accompanied by rash Probable: A case that meets the clinical case definition, has noncontributory or no serologic or virologic testing, and is not epidemiologically linked to a confirmed case Confirmed: A case that is laboratory confirmed or that meets the clinical case definition and is epidemiologically linked to a confirmed case; a laboratory-confirmed case need not meet the clinical case definition Management Treatment of measles is essentially supportive care, as follows: Maintenance of good hydration and replacement of fluids lost through diarrhea or emesis IV rehydration may be necessary if dehydration is severe Vitamin A supplementation should be considered Postexposure prophylaxis should be considered in unvaccinated contacts; timely tracing of contacts should be a priority. Patients should receive regular follow-up care with a primary care physician for surveillance of complications arising from the infection. Vitamin A supplementation The World Health Organization recommends vitamin A supplementation for all children diagnosed with measles, regardless of their country of residence, based on their age, [10] as follows: Infants younger than 6 months: 50,000 IU/day PO for 2 doses Age 6-11 months: 100,000 IU/day PO for 2 doses Older than 1 year: 200,000 IU/day PO for 2 doses Children with clinical signs of vitamin A deficiency: The first 2 doses as appropriate for age, then a third age-specific dose given 2-4 weeks later
Background
Measles, also known as rubeola, is one of the most contagious infectious diseases, with at least a 90% secondary infection rate in susceptible domestic contacts. It can affect people of all ages, despite being considered primarily a childhood illness. Measles is marked by prodromal fever, cough, coryza, conjunctivitis, and pathognomonic enanthem (ie, Koplik spots), followed by an erythematous maculopapular rash on the third to seventh day. Infection confers life-long immunity.
A generalized immunosuppression that follows acute measles frequently predisposes patients to bacterial otitis media and bronchopneumonia. In approximately 0.1% of cases, measles causes acute encephalitis. Subacute sclerosing panencephalitis (SSPE) is a rare chronic degenerative disease that occurs several years after measles infection.
After an effective measles vaccine was introduced in 1963, the incidence of measles decreased significantly. Nevertheless, measles remains a common disease in certain regions and continues to account for nearly 50% of the 1.6 million deaths caused each year by vaccine-preventable childhood diseases. The incidence of measles in the United States and worldwide is increasing, with outbreaks being reported particularly in populations with low vaccination rates. [11]
Maternal antibodies play a significant role in protection against infection in infants younger than 1 year and may interfere with live-attenuated measles vaccination. A single dose of measles vaccine administered to a child older than 12 months induces protective immunity in 95% of recipients. Because measles virus is highly contagious, a 5% susceptible population is sufficient to sustain periodic outbreaks in otherwise highly vaccinated populations.
A second dose of vaccine, now recommended for all school-aged children in the United States, [12] induces immunity in about 95% of the 5% who do not respond to the first dose. Slight genotypic variation in recently circulating strains has not affected the protective efficacy of live-attenuated measles vaccines.
Unsubstantiated claims that suggest an association between the measles vaccine and autism have resulted in reduced vaccine use and contributed to a recent resurgence of measles in countries where immunization rates have fallen to below the level needed to maintain herd immunity. [13, 14]
Considering that for industrialized countries such as the United States, endemic transmission of measles may be reestablished if measles immunity falls to less than 93-95%, efforts to ensure high immunization rates among people in both developed and developing countries must be sustained.
Supportive care is normally all that is required for patients with measles. Vitamin A supplementation during acute measles significantly reduces risks of morbidity and mortality.
For patient education resources, see Bacterial and Viral Infections, as well as Measles and Skin Rashes in Children.
Pathophysiology
In temperate areas, the peak incidence of infection occurs during late winter and spring. Infection is transmitted via respiratory droplets, which can remain active and contagious, either airborne or on surfaces, for up to 2 hours. Initial infection and viral replication occur locally in tracheal and bronchial epithelial cells. After 2-4 days, measles virus infects local lymphatic tissues, perhaps carried by pulmonary macrophages. Following the amplification of measles virus in regional lymph nodes, a predominantly cell-associated viremia disseminates the virus to various organs prior to the appearance of rash.
Measles virus infection causes a generalized immunosuppression marked by decreases in delayed-type hypersensitivity, interleukin (IL)-12 production, and antigen-specific lymphoproliferative responses that persist for weeks to months after the acute infection. Immunosuppression may predispose individuals to secondary opportunistic infections, [15] particularly bronchopneumonia, a major cause of measles-related mortality among younger children.
In individuals with deficiencies in cellular immunity, measles virus causes a progressive and often fatal giant cell pneumonia.
In immunocompetent individuals, wild-type measles virus infection induces an effective immune response, which clears the virus and results in lifelong immunity. [16]
Etiology
The cause of measles is the measles virus, a single-stranded, negative-sense enveloped RNA virus of the genus Morbillivirus within the family Paramyxoviridae. Humans are the natural hosts of the virus; no animal reservoirs are known to exist. This highly contagious virus is spread by coughing and sneezing via close personal contact or direct contact with secretions.
Risk factors for measles virus infection include the following: Children with immunodeficiency due to HIV or AIDS, leukemia, alkylating agents, or corticosteroid therapy, regardless of immunization status Travel to areas where measles is endemic or contact with travelers to endemic areas Infants who lose passive antibody before the age of routine immunization
Risk factors for severe measles and its complications include the following:
Malnutrition
Underlying immunodeficiency
Pregnancy
Vitamin A deficiency
Epidemiology
United States statistics The practice of administering 2 doses of live-attenuated measles vaccine to children to prevent school outbreaks of measles was implemented when the vaccine was first licensed in 1963. The immunization program resulted in a decrease of more than 99% in reported incidence. From 1989 to 1991, a major resurgence occurred, affecting primarily unvaccinated preschoolers. This measles resurgence resulted in 55,000 cases and 130 deaths [17] and prompted the recommendation that a second dose of measles vaccine be given to preschoolers in a mass vaccination campaign that led to the effective elimination in the United States of endemic transmission of the measles virus. [18] By 1993, vaccination programs had interrupted the transmission of indigenous measles virus in the United States; since then, most reported cases of measles in the United States have been linked to international travel. [19] By 1997-1999, the incidence of measles had been reduced to a historic low (< 0.5 cases per million persons). From 1997 to 2004, the reported incidence was as low as 37-116 cases per year. From November 2002 on, measles was not considered an endemic disease in the United States. From 2000 through 2007, an average of 63 cases were reported annually to the US Centers for Disease Control and Prevention (CDC). In 2004, 34 cases were reported; after that all-time low, however, the annual incidence began to increase, with most cases linked either directly or indirectly to international travel. Incomplete vaccination rates facilitate the spread once the virus is imported to the United States. In 2005, 66 cases of measles were reported to the CDC. [20] Of these, 34 were linked with a single outbreak in Indiana associated with the return of an unvaccinated 17-year-old American traveling in Romania. In 2006, a total of 49 confirmed cases were reported in the United States. From January to June 2008, 131 cases of measles were reported to the CDC. [21] Although 90% of those 131 cases were associated with importation of the virus to the United States from overseas, 91% of those affected were unvaccinated or had unknown or undocumented vaccination status. At least 47% of the 131 measles infections were in school-aged children whose parents chose not to have them vaccinated. [21] In the period from January 1 to May 20, 2011, a total of 118 cases were reported to the CDC; this represents the highest reported number of measles cases for the same period since 1996. [22] Of the 118 cases, 105 (89%) were associated with importation; the source of the remaining 13 cases could not be ascertained. In all, 105 (89%) of the 118 patients were unvaccinated; 24 (20%) were persons 12 months to 19 years of age whose parents claimed a religious or personal exemption. Approximately half of the 118 cases—58, or 49%—were accounted for by 9 outbreaks. The largest of these outbreaks involved 21 persons in Minnesota, in a setting where parental concerns about the safety of measles, mumps, and rubella (MMR) vaccine caused many children to go unvaccinated. [23] As a result of this outbreak, many persons were exposed, and at least 7 infants too young to receive MMR vaccine were infected. Although the elimination of endemic measles transmission in the US in 2000 was sustained through at least 2011, according to a CDC study, cases continue to be caused by virus brought into the country by travelers from abroad, with spread occurring largely among unvaccinated individuals. In 88% of the cases reported between 2000 and 2011, the virus originated from a country outside the US, and 2 out of every 3 individuals who developed measles were unvaccinated. Moreover, the director of the CDC noted that, in 2013, US measles cases increased threefold from the previous median, to 175 cases. [1, 2] Most of these cases were outbreaks in children whose parents had refused immunization. This trend of increased incidence has continued into 2014. From January 1 to May 23, 2014, 288 confirmed cases were reported to the CDC, a figure that exceeds the highest reported annual total number of cases (220 cases in 2011) since measles was declared eliminated in the United States in 2000. Of the 288 cases, 200 (69%) occurred in unvaccinated individuals and 58 (20%) in persons with unknown vaccination status. Nearly all of the 2014 cases reported thus far (280 [97%]) were associated with importations from at least 18 countries. Eighteen states and New York City reported measles infections during this period, and 15 outbreaks accounted for 79% of reported cases, including a large ongoing outbreak in Ohio primarily among unvaccinated Amish persons, with 138 cases reported thus far. [3] A research letter by Clemmons et al reported 1789 cases of measles in the US from 2001 to 2015, of which, 69.5% (1243 cases) were from unvaccinated individuals. The study also reported that incidence per million population increased from 0.28 in 2001 to 0.56 in 2015. [24] Despite the highest recorded immunization rates in history, young children who are not appropriately vaccinated may experience more than a 60-fold increase in risk of disease due to exposure to imported measles cases from countries that have not yet eliminated the disease.
International statistics In developing countries, measles affects 30 million children a year and causes 1 million deaths. Measles causes 15,000-60,000 cases of blindness per year. In 1998, the cases of measles per 100,000 total population reported to the World Health Organization (WHO) was 1.6 in the Americas, 8.2 in Europe, 11.1 in the Eastern Mediterranean region, 4.2 in South East Asia, 5.0 in the Western Pacific region, and 61.7 in Africa. In 2006, only 187 confirmed cases were reported in the Western Hemisphere (mainly in Venezuela, Mexico, and the United States). [25] Between 2000 and 2008, the number of worldwide measles cases reported to the WHO and the United Nations Children’s Fund (UNICEF) declined by 67% (from 852,937 to 278,358). During the same 8-year period, global measles mortality dropped by 78%. However, it is believed that global measles incidence and mortality remain underreported, with many countries, particularly those with the highest disease burden, lacking complete, reliable surveillance data. [26] Since 2008, France has been experiencing an outbreak of measles, which has not yet begun to slacken. [27] Over the same period, outbreaks have also been occurring in the 46 countries of the WHO African Region. [28] Worldwide, most reported cases of measles continue to be from Africa.
Age-related demographics Although measles is historically a disease of childhood, infection can occur in unvaccinated or partially vaccinated individuals of any age or in those with compromised immunity. Unvaccinated young children are at the highest risk. Age-specific attack rates may be highest in susceptible infants younger than 12 months, school-aged children, or young adults, depending on local immunization practices and incidence of the disease. Complications such as otitis media, bronchopneumonia, laryngotracheobronchitis (ie, croup), and diarrhea are more common in young children. Of the 66 cases of measles reported in the United States in 2005, 7 (10.6%) involved infants, 4 (6.1%) involved children aged 1-4 years, 33 (50%) involved persons aged 5-19 years, 7 (10.6%) involved adults aged 20-34 years, and 15 (22.7%) involved adults older than 35 years. [20] Among the 118 US patients reported to have measles between January 1 and May 20, 2011, age ranged from 3 months to 68 years. [22] More than half were younger than 20 years: 18 (15%) were younger than 12 months, 24 (20%) were 1-4 years old, 23 (19%) were 5-19 years old, and 53 (45%) were 20 years of age or older. In heavily populated, underdeveloped countries, measles is most common in children younger than 2 years.
Sex- and race-related demographics
Unvaccinated males and females are equally susceptible to infection by the measles virus. Excess mortality following acute measles has been observed among females at all ages, but it is most marked in adolescents and young adults. Excessive non–measles-related mortality has also been observed among female recipients of high-titer measles vaccines in Senegal, Guinea Bissau, and Haiti. [29]
Measles affects people of all races.
Prognosis
The prognosis for measles is generally good, with infection only occasionally being fatal. The CDC reports the childhood mortality rate from measles infection in the United States to be 0.1-0.2%. However, many complications and sequelae may develop (see Complications), and measles is a major cause of childhood blindness in developing countries. Globally, measles remains one of the leading causes of death in young children. According to the CDC, measles caused an estimated 197,000 deaths worldwide in 2007. [25] An estimated 85% of these deaths occurred in Africa and Southeast Asia. From 2000-2007, deaths worldwide fell by 74% (to 197,000 from an estimated 750,000), thanks to the partnership of several global organizations. Case-fatality rates are higher among children younger than 5 years. The highest fatality rates are among infants aged 4-12 months and in children who are immunocompromised because of human immunodeficiency virus (HIV) infection or other causes.
Complications of measles are more likely to occur in persons younger than 5 years or older than 20 years, and morbidity and mortality are increased in persons with immune deficiency disorders, malnutrition, vitamin A deficiency, and inadequate vaccination. Croup, encephalitis, and pneumonia are the most common causes of death associated with measles. Measles encephalitis, a rare but serious complication, has a 10% mortality.
Measles Clinical Presentation
History The patient history is notable for exposure to the virus. The incubation period from exposure to onset of measles symptoms ranges from 7 to 14 days (average, 10-12 days). Patients are contagious from 1-2 days before the onset of symptoms. Healthy children are also contagious during the period from 3-5 days before the appearance of the rash to 4 days after the onset of rash. On the other hand, immunocompromised individuals can be contagious during the duration of the illness.The first sign of measles is usually a high fever (often >104o F [40o C]) that typically lasts 4-7 days. This prodromal phase is marked by malaise, fever, anorexia, and the classic triad of conjunctivitis (see the image below), cough, and coryza (the “3 Cs”). Other possible associated symptoms include photophobia, periorbital edema, and myalgias.
📷Measles conjunctivitis.
The characteristic enanthem generally appears 2-4 days after the onset of the prodrome and lasts 3-5 days. Small spots (Koplik spots) can be seen inside the cheeks during this early stage (see the image below).
📷Koplik spots in measles. Photograph courtesy of World Health Organization.
The exanthem usually appears 1-2 days after the appearance of Koplik spots; mild pruritus may be associated. On average, the rash develops about 14 days after exposure, starting on the face and upper neck (see the image below) and spreading to the extremities. Immunocompromised patients may not develop a rash.
The entire course of uncomplicated measles, from late prodrome to resolution of fever and rash, is 7-10 days. Cough may be the final symptom to appear.
Modified and atypical measles
Modified measles is a milder form of measles that occurs in individuals who have received serum immunoglobulin after their exposure to the measles virus. Similar but milder symptoms and signs may still occur, but the incubation period may be as long as 21 days.
Atypical measles occurs in individuals who were vaccinated with the original killed-virus measles vaccine between 1963 and 1967 and who have incomplete immunity. After exposure to the measles virus, a mild or subclinical prodrome of fever, headache, abdominal pain, and myalgias precedes a rash that begins on the hands and feet and spreads centripetally. The eruption is accentuated in the skin folds and may be macular, vesicular, petechial, or urticarial. The live-attenuated vaccine replaced the killed vaccine in 1967 and is not associated with atypical measles.
Physical Examination
Enanthem
Near the end of the prodrome, Koplik spots (ie, bluish-gray specks or “grains of sand” on a red base) appear on the buccal mucosa opposite the second molars (see the image below).
📷Enanthem of measles (Koplik spots). The Koplik spots generally are first seen 1-2 days before the appearance of the rash and last until 2 days after the rash appears. This enanthem begins to slough as the rash appears. Although this is the pathognomonic enanthem of measles, its absence does not exclude the diagnosis.
Exanthem
Blanching, erythematous macules and papules begin on the face at the hairline, on the sides of the neck, and behind the ears (see the images below). Within 48 hours, they coalesce into patches and plaques that spread cephalocaudally to the trunk and extremities, including the palms and soles, while beginning to regress cephalocaudally, starting from the head and neck. Lesion density is greatest above the shoulders, where macular lesions may coalesce. The eruption may also be petechial or ecchymotic in nature.
📷Morbilliform rash.View Media Gallery
Patients appear most ill during the first or second day of the rash. The exanthem lasts for 5-7 days before fading into coppery brown hyperpigmented patches, which then desquamate. The rash may be absent in patients with underlying deficiencies in cellular immunity.
Complications
Most complications of measles occur because the measles virus suppresses the host’s immune responses, resulting in a reactivation of latent infections or superinfection by a bacterial pathogen. Consequently, pneumonia, whether due to the measles virus itself, to tuberculosis, to or another bacterial etiology, is the most frequent complication. Pleural effusion, hilar lymphadenopathy, hepatosplenomegaly, hyperesthesia, and paresthesia may also be noted. Complications of measles are more likely to occur in persons younger than 5 years or older than 20 years, and complication rates are increased in persons with immune deficiency disorders, malnutrition, vitamin A deficiency, and inadequate vaccination. Immunocompromised children and adults are at increased risk for severe infections and superinfections. Common infectious complications include otitis media, interstitial pneumonitis, [30] bronchopneumonia, laryngotracheobronchitis (ie, croup), exacerbation of tuberculosis, transient loss of hypersensitivity reaction to tuberculin skin test, encephalomyelitis, diarrhea, sinusitis, stomatitis, subclinical hepatitis, lymphadenitis, and keratitis, which can lead to blindness. In fact, measles remains a common cause of blindness in many developing countries. Rare complications include hemorrhagic measles, purpura fulminans, hepatitis, disseminated intravascular coagulation (DIC), subacute sclerosing panencephalitis (SSPE), thrombocytopenia, appendicitis, ileocolitis, pericarditis, myocarditis, acute pancreatitis, [31] and hypocalcemia. [32] Transient hepatitis may occur during an acute infection. Approximately 1 of every 1,000 patients develops acute encephalitis, which often results in permanent brain damage and is fatal in about 10% of patients. In children with lymphoid malignant diseases, delayed-acute measles encephalitis may develop 1-6 months after the acute infection and is generally fatal. An even rarer complication is SSPE, a degenerative CNS disease that can result from a persistent measles infection. SSPE is characterized by the onset of behavioral and intellectual deterioration and seizures years after an acute infection (the mean incubation period for SSPE is approximately 10.8 years). The complications of measles in the pregnant mother include pneumonitis, hepatitis, subacute sclerosing panencephalitis, premature labor, spontaneous abortion, and preterm birth of the fetus. Perinatal transmission rates are low.
Diagnostic Considerations
The diagnosis of measles is usually determined from the classic clinical picture, including the classic triad of cough, coryza, and conjunctivitis; the pathognomonic Koplik spots; and the characteristic cephalocaudal progression of the morbilliform exanthem.
It is worthwhile to be mindful of the syndrome known as atypical measles, which has been described in individuals who were infected with wild measles virus several years after immunization with a killed measles vaccine (a vaccine used in the United States from 1963-1967). This syndrome tends to be more prolonged and severe than regular measles and is marked by a prolonged high fever, pneumonitis, and a rash that begins peripherally and may be urticarial, maculopapular, hemorrhagic, and/or vesicular.
The assumed pathogenesis of atypical measles is hypersensitivity to measles virus in a partially immune host. Laboratory tests reveal a very low measles antibody titer early in the course of the disease, followed soon thereafter by the appearance of an extremely high measles immunoglobulin G (IgG) antibody titer (eg, 1:1,000,000) in the serum.
Other diagnoses to be considered include the following:
Kawasaki disease
Dengue
Serum sickness
Syphilis
Systemic lupus erythematosus
Toxic shock syndrome
Differential Diagnoses
Pediatric Sepsis
Measles Workup
Approach Considerations Although the diagnosis of measles is usually determined from the classic clinical picture (see Clinical), laboratory identification and confirmation of the diagnosis are necessary for the purposes of public health and outbreak control. Laboratory confirmation is achieved by means of serologic testing for immunoglobulin G (IgG) and M (IgM) antibodies, isolation of the virus, and reverse-transcriptase polymerase chain reaction (RT-PCR) evaluation.A complete blood cell count (CBC) may reveal leukopenia with a relative lymphocytosis and thrombocytopenia. Liver function test (LFT) results may reveal elevated transaminase levels in patients with measles hepatitis.Consult public health or infectious disease specialists for recommendations and guidelines for diagnostic confirmation of cases and prophylaxis of susceptible contacts.Case reporting Because the transmission of indigenous measles has been interrupted in the United States and all recent US epidemics have been linked to imported cases, immediately reporting any suspected case of measles to a local or state health department is imperative, as is obtaining serum for IgM antibody testing as soon as possible (ie, on or after the third day of rash).
The US Centers for Disease Control and Prevention (CDC) clinical case definition for reporting purposes requires only the following:
Generalized rash lasting 3 days or longer
Temperature of 101.0°F (38.3°C) or higher
Cough, coryza, or conjunctivitisFurther, for reporting purposes for the CDC, cases are classified as follows:
Suspected - Any febrile illness accompanied by rash
Probable - A case that meets the clinical case definition, has noncontributory or no serologic or virologic testing, and is not epidemiologically linked to a confirmed case
Confirmed - A case that is laboratory confirmed or that meets the clinical case definition and is epidemiologically linked to a confirmed case; a laboratory-confirmed case need not meet the clinical case definition
Antibody Assays
Immunoglobulin M
The measles virus sandwich-capture IgM antibody assay, offered through many local health departments and through the CDC, is the quickest method of confirming acute measles. Because IgM may not be detectable during the first 2 days of rash, obtain blood for measles-specific IgM on the third day of the rash or on any subsequent day up to 1 month after onset to avoid a false-negative IgM result.
Among persons with confirmed measles infection, the seropositivity rate for first samples is about 77% when collected within 72 hours; the rate rises to 100% when collected 4-11 days after rash onset. [33] Although the measles serum IgM level remains positive 30-60 days after the illness in most individuals, the IgM titer may become undetectable in some subjects at 4 weeks after rash onset. False-positive results can occur in patients with rheumatologic diseases, parvovirus B19 infection, or infectious mononucleosis.
Immunoglobulin G
Laboratories can confirm measles by demonstrating more than a 4-fold rise in IgG antibodies between acute and convalescent sera, although relying solely on rising IgG titers for the diagnosis delays treatment considerably. The earlier the acute serum is drawn, the more reliable the results. IgG antibodies may be detectable 4 days after the onset of the rash, although most cases have detectable IgG antibodies by about a week after rash onset.
Accordingly, it is recommended that specimens be drawn on the seventh day after rash onset. Blood drawn for convalescent serum should be drawn 10-14 days after that drawn for acute serum, and the acute and convalescent sera should be tested simultaneously as paired sera.
Patients with subacute sclerosing panencephalitis (SSPE) have unusually high titers of measles antibody in their serum and cerebrospinal fluid (CSF). The earliest confirmation of measles using IgG antibodies takes about 3 weeks from the onset of illness, a delay too long to permit implementation of effective control measures.
In atypical measles, laboratory evaluation of serum/blood reveals very low titers of measles antibody early in the course of the disease, followed by extremely high measles IgG antibody titers (eg, 1:1,000,000).
IgG levels can be explained by current infection, immunity due to past infection or vaccination, or maternal antibodies present in infants younger than 15 months.
Viral Culture
Throat swabs and nasal swabs can be sent on viral transport medium or a viral culturette swab to isolate the measles virus. Urine specimens can be sent in a sterile container for viral culture.
Viral genotyping in a reference laboratory may determine whether an isolate is endemic or imported. In immunocompromised patients, who may have poor antibody responses that preclude serologic confirmation of measles, isolation of the virus from infected tissue or identification of measles antigen by means of immunofluorescence may be the only feasible method of confirming the diagnosis.
Polymerase Chain Reaction
Reverse-transcription polymerase chain reaction (PCR) evaluation is highly sensitive at visualizing measles virus RNA in blood, throat, nasopharyngeal, or urine specimens and, where available, can be used to rapidly confirm the diagnosis of measles. [9] According to the CDC, the samples should be collected at the first contact with a suspected case of measles when the serum sample for diagnosis is drawn.
Studies for Suspected Complications
Chest radiography
If bacterial pneumonia is suspected, perform chest radiography. The frequent occurrence of measles pneumonia, even in uncomplicated cases, limits the predictive value of chest radiography for bacterial bronchopneumonia.
Lumbar puncture
If encephalitis is suspected, perform a lumbar puncture. CSF examination reveals the following:
Increased protein
Normal glucose
Mild pleocytosis with a predominance of lymphocytes
Tissue Analysis and Histologic Findings A skin biopsy from a lesion of the morbilliform eruption shows spongiosis and vesiculation in the epidermis with scattered dyskeratotic keratinocytes. Occasional lymphoid multinucleated giant cells (≤ 100 nm in diameter) can be identified in biopsies of Koplik spots, in dermal or epithelial rashes, in hair follicles and acrosyringium and in lung or lymphoid tissue. These findings are not specific, but they are suggestive of a viral exanthem. Brain biopsies of patients with measles encephalitis can reveal demyelination, vascular cuffing, gliosis, and infiltration of fat-laden macrophages near blood vessel walls.
Measles Treatment & Management
Approach Considerations
Treatment of measles is essentially supportive care with maintenance of good hydration and replacement of fluids lost through diarrhea or emesis. Intravenous (IV) rehydration may be necessary if dehydration is severe.Vitamin A supplementation, especially in children and patients with clinical signs of vitamin A deficiency, should be considered. Postexposure prophylaxis should be considered in unvaccinated contacts; timely tracing of contacts should be a priority.Patients should receive regular follow-up care with a primary care physician for surveillance of complications arising from the infection (see Complications).
Supportive Care
Supportive care is normally all that is required for patients with measles. Hospitalization may be indicated for treatment of measles complications (eg, bacterial superinfection, pneumonia, dehydration, croup).
Secondary infections (eg, otitis media or bacterial pneumonia) should be treated with antibiotics; Patients with severe complicating infections (eg, encephalomyelitis) should be admitted for observation and antibiotics, as appropriate to their clinical condition.
Occasionally, IV rehydration is required; patients may be markedly febrile and consequently may become dehydrated. Fever management with standard antipyretics is appropriate.
Airborne precautions are indicated for hospitalized children during the period of communicability (ie, 3-5 day before the appearance of a rash to 4 days after the rash develops in healthy children and for the duration of illness in patients who are immunocompromised). Susceptible health care workers should be excused from work from the fifth to the 21st day after exposure.
Antiviral Therapy
Measles virus is susceptible to ribavirin in vitro. Although ribavirin (either IV or aerosolized) has been used to treat severely affected and immunocompromised adults with acute measles or subacute sclerosing panencephalitis (SSPE), [34] no controlled trials have been conducted; ribavirin is not approved by the US Food and Drug Administration (FDA) for this indication, and such use should be considered experimental.
Vitamin A Supplementation
Vitamin A supplements have been associated with reductions of approximately 50% in morbidity and mortality and appear to help prevent eye damage and blindness.
Because vitamin A deficiency is associated with severe disease from measles, The World Health Organization recommends all children diagnosed with measles should receive vitamin A supplementation regardless of their country of residence, based on their age, [10] as follows:
Infants younger than 6 months – 50,000 IU/day PO for 2 doses
Age 6-11 months - 100,000 IU/day PO for 2 doses
Older than 1 year - 200,000 IU/day PO for 2 doses
Children with clinical signs of vitamin A deficiency – The first 2 doses as appropriate for age, then a third age-specific dose given 2-4 weeks later
Postexposure Prophylaxis Postexposure prophylaxis should be considered in unvaccinated contacts. Prevention or modification of measles in exposed susceptible individuals involves the administration of measles virus vaccine or human immunoglobulin (Ig).
Measles virus vaccine In the United States, the measles virus vaccine is routinely administered along with the mumps and rubella vaccines as the measles-mumps-rubella (MMR) vaccine. The vaccine is preventive if administered within 3 days of exposure.
Contraindications to the vaccine include immunodeficiency; generalized cancers (eg, leukemia, lymphoma); active, untreated tuberculosis; and therapy with immunosuppressants. HIV infection is only a contraindication in the presence of severe immunosuppression (ie, CD4 counts lower than 15%). The vaccine should be deferred until after delivery in pregnant patients and for at least 5 months in anyone who has received antibody (ie, plasma, whole blood, any immune globulin). [35, 36]
Human immunoglobulin Human Ig prevents or modifies disease in susceptible contacts if administered within 6 days of exposure.
Human Ig is given to the following individuals: Those who are immunocompromised Infants aged 6 months to 1 year (morbidity is high in children younger than 1 year Infants younger than 6 months who are born to mothers without measles immunity Pregnant women In contacts for whom the vaccine should be deferred (eg, pregnant patients), human Ig 0.25 mL/kg (not to exceed 15 mL) should be administered intramuscularly (IM) immediately after exposure, and the measles vaccine should be given 6 months later. Exposed immunocompromised patients with a contraindication to vaccination should receive human Ig 0.5 mL/kg (not to exceed 15 mL) IM.
Medication
Medication Summary
Medications used in the treatment or prevention of measles include vitamin A, antivirals (eg, ribavirin), measles virus vaccine, and human immunoglobulin (Ig).
Vitamins
Class Summary
Vitamin A treatment for children with measles in developing countries has been associated with a marked reduction in morbidity and mortality. The World Health Organization (WHO) recommends vitamin A administration to all children with acute measles, regardless of their country of residence.
Of note, low serum concentrations of vitamin A are found in children with severe measles in the United States. Thus, two doses of vitamin A given 24 hours apart are recommended. A third age-specific dose should be given 2 to 4 weeks later to children with clinical signs and symptoms of vitamin A deficiency.
Vitamin A (Aquasol A, A-25, Gordons-Vite A)
Vitamin A is a fat-soluble vitamin needed for growth of skin, bones, and male and female reproductive organs.
Antivirals
Class Summary
Measles virus is susceptible to ribavirin in vitro. Although ribavirin (either IV or aerosolized) has been used to treat severely affected and immunocompromised adults with acute measles or SSPE (IV plus intrathecal high-dose interferon alfa), no controlled trials have been conducted; ribavirin is not approved by the US Food and Drug Administration (FDA) for this indication, and such use should be considered experimental.
Ribavirin (Virazole, Rebetol, Ribasphere, Copegus)
Ribavirin, a guanosine analogue, is for experimental use only. Its mechanism of action is not fully defined but relates to alteration of cellular nucleotide pools and of viral messenger RNA information.
Vaccines
Class Summary
In the United States, measles virus vaccine is usually given along with attenuated rubella and mumps viruses as the measles-mumps-rubella (MMR) vaccine. The following measles vaccines are available in the United States:
- Live measles mumps, and rubella virus vaccine (M-M-R II)
- Live measles, mumps, rubella, and varicella virus vaccine (ProQuad)
Measles mumps and rubella vaccine, live (M-M-R II)
The live MMR vaccine is used to induce active immunity against viruses that cause measles, mumps, and rubella.
Measles, mumps, rubella, and varicella virus vaccine (ProQuad)
This is a live vaccine that induces active immunity against viruses that cause measles, mumps, rubella, and varicella.
Immunoglobulins Class Summary Human Ig prevents or modifies measles in susceptible individuals if administered within 6 days of exposure. Immune globulin IM (IGIM) GamaSTAN, Gammaked, Hizentra, Gamunex-C) Immune globulin IM (IGIM) is a transient source of IgG. It is indicated for all susceptible contacts of patients with measles who reside in the same household who are pregnant, immunocompromised, or aged 6-12 months; it is also indicated for infants younger than 6 months who were born to mothers without measles immunity and also all children and adolescents with HIV infection who are exposed to measles, regardless of measles immunization status, unless they have received IV Ig (400 mg/kg as part of routine immunoprophylaxis) within 3 weeks of exposure
References
1 Lowes R. Three-Fold Increase in Measles Warrants Vigilance, CDC Says. Medscape Medical News. Available at http://www.medscape.com/viewarticle/815514. Accessed: December 9, 2013.
2 Papania MJ, Wallace GS, Rota PA, et al. Elimination of Endemic Measles, Rubella, and Congenital Rubella Syndrome From the Western Hemisphere: The US Experience. JAMA Pediatr. 2013 Dec 5. [Medline].
3 Gastanaduy PA, Redd SB, Fiebelkorn AP, et al. Measles - United States, January 1-May 23, 2014. MMWR Morb Mortal Wkly Rep. 2014 Jun 6. 63(22):496-499. [Medline].
3 California Department of Public Health Confirms 59 Cases of Measles. California Department of Public Health. Available at http://www.cdph.ca.gov/Pages/NR15-008.aspx. Accessed: January 23, 2015.
5 Gastañaduy PA, Budd J, Fisher N, Redd SB, Fletcher J, Miller J, et al. A Measles Outbreak in an Underimmunized Amish Community in Ohio. N Engl J Med. 2016 Oct 6. 375 (14):1343-1354. [Medline].
6 Parry N. Containment Cuts Measles Spread in Undervaccinated Population. Medscape Medical News. Available at http://www.medscape.com/viewarticle/869872. October 05, 2016; Accessed: November 10, 2016.
7 Harrison L. AAP updates measles recommendations. Medscape Medical News. WebMD Inc. Available at http://www.medscape.com/viewarticle/839688. Accessed: March 31, 2015.2015
8 Report of the Committee on Infectious Diseases. Early Release from Red Book. American Academy of Pediatrics. Available at http://redbook.solutions.aap.org/DocumentLibrary/2015RedBookMeasles.pdf. Accessed: March 31, 2015.
9 Bar-On S, Ochshorn Y, Halutz O, Aboudy Y, Many A. Detection of measles virus by reverse-transcriptase polymerase chain reaction in a placenta. J Matern Fetal Neonatal Med. 2010 Aug. 23(8):935-7. [Medline].
10 American Academy of Pediatrics. Measles. Pickering LK, ed. Red Book: Report of the Committee on Infectious Disease. Elk Grove, Ill: AAP; 2006. 441-52.
11 Sabella C. Measles: not just a childhood rash. Cleve Clin J Med. 2010 Mar. 77(3):207-13. [Medline].
12 [Guideline] Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years---United States, 2009. CDC Recommended Vaccine Schedule. 2008 Dec. 57(51;52):[Full Text].
13 Meissner HC, Strebel PM, Orenstein WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics. 2004. 114(4):1065-9. [Medline]. [Full Text].
14 Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet. 2004. 11-17;364(9438):963-9. [Medline].
15 Schneider-Schaulies S, Schneider-Schaulies J. Measles virus-induced immunosuppression. Curr Top Microbiol Immunol. 2009. 330:243-69. [Medline].
16 Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J. 1990 Feb. 9(2):101-10. [Medline].
17 Reported vaccine-preventable diseases--United States, 1993, and the childhood immunization initiative. MMWR Morb Mortal Wkly Rep. 1994 Feb 4. 43(4):57-60. [Medline].
18 Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis. 2004 May 1. 189 Suppl 1:S1-3. [Medline].
19 Coleman KP, Markey PG. Measles transmission in immunized and partially immunized air travellers. Epidemiol Infect. 2010 Jul. 138(7):1012-5. [Medline].
20 Measles--United States, 2005. MMWR Morb Mortal Wkly Rep. 2006 Dec 22. 55(50):1348-51. [Medline].
21 Update: measles--United States, January-July 2008. MMWR Morb Mortal Wkly Rep. 2008 Aug 22. 57(33):893-6. [Medline].
22 Centers for Disease Control and Prevention. Measles—United States, January–May 20, 2011. MMWR Morb Mortal Wkly Rep. 2011 May 24;60(Early Release):1-4:
23 Notes from the field: Measles outbreak--Hennepin County, Minnesota, February-March 2011. MMWR Morb Mortal Wkly Rep. 2011 Apr 8. 60(13):421. [Medline].
24 Clemmons NS, Wallace GS, Patel M, Gastañaduy PA. Incidence of Measles in the United States, 2001-2015. JAMA. 2017 Oct 3. 318 (13):1279-1281. [Medline].
25 Centers for Disease Control and Prevention. Program in brief: Measles Mortality Reduction and Regional Global Measles Elimination. Available at http://www.cdc.gov/ncird/progbriefs/downloads/global-measles-elim.pdf. Accessed: April 14, 2009.
26 Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep. 2009 Dec 4. 58(47):1321-6. [Medline].
27 Benkimoun P. Outbreak of measles in France shows no signs of abating. BMJ. 2011 May 20. 342:d3161. [Medline].
28 Measles outbreaks and progress toward measles preelimination --- African region, 2009-2010. MMWR Morb Mortal Wkly Rep. 2011 Apr 1. 60(12):374-8. [Medline].
29 Garenne M. Sex differences in measles mortality: a world review. Int J Epidemiol. 1994 Jun. 23(3):632-42. [Medline].
30 Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous. Clin Infect Dis Sep. 1994. 19(3):454-62. [Medline].
31 Fusilli G, De Mitri B. Acute pancreatitis associated with the measles virus: case report and review of literature data. Pancreas. 2009 May. 38(4):478-80. [Medline].
32 Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004 May 1. 189 Suppl 1:S4-16. [Medline].
33 Helfand RF, Heath JL, Anderson LJ, et al. Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset. J Infect Dis. 1997 Jan. 175(1):195-9. [Medline].
34 Hosoya M, Shigeta S, Mori S, et al. High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2001 Mar. 45(3):943-5. [Medline].
35 The Merck Manuals Online Medical Library. Available at http://www.merck.com/mmpe/sec14/ch193/ch193b.html.
36 MMR-II vaccine insert. Available at http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf.
37 Immunization Schedules. Updated August 25, 2010. Centers for Disease Control and Prevention (CDC). Available at http://www.cdc.gov/vaccines/recs/schedules/default.htm. Accessed: May 25, 2011.
38 Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of age on the risk of fever and seizures following immunization With measles-containing vaccines in children. JAMA Pediatr. 2013 Oct 14. [Medline].
39 Henderson D. Measles vaccine: lower seizure risk when given early on. Medscape Medical News. October 14, 2013. [Full Text].
40Hand L. MMR: ACIP Vaccine Recommendations, Japan Rubella Outbreak. Available at http://www.medscape.com/viewarticle/806524. Accessed: July 15, 2013.
41 Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Jun 14. 62:1-34. [Medline].
42 Measles imported by returning U.S. travelers aged 6-23 months, 2001-2011. MMWR Morb Mortal Wkly Rep. 2011 Apr 8. 60(13):397-400. [Medline].
43 Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul. 126(1):e1-8. [Medline].
44 Hviid A. Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. J Pediatr. 2011 Jan. 158(1):170. [Medline]. [Full Text].45 45
45 [Guideline] Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 May 7. 59:1-12. [Medline]. [Full Text].
46 [Guideline] American Academy of Pediatrics; Committee on Infectious Diseases. Policy Statement--Prevention of Varicella: Update of Recommendations for Use of Quadrivalent and Monovalent Varicella Vaccines in Children. Pediatrics. 2011 Aug 28. [Medline].
47 Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002 Nov 7. 347(19):1477-82. [Medline].
48 Mrozek-Budzyn D, Kieltyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J. 2010 May. 29(5):397-400. [Medline].
49 Measles Initiative highlights the importance of adherence to global goals and strategies (news release). Available at http://bit.ly/mULNYb. Accessed: May 26, 2011.
50 Measles (Rubeola): Measles Cases and Outbreaks. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/measles/cases-outbreaks.html. June 3, 2019; Accessed: June 6, 2019.
51 Brown T. Measles Cases Continue to Rise, Highest Since 1992. Medscape Medical News. Available at https://www.medscape.com/viewarticle/913916. June 4, 2019; Accessed: June 6, 2019.
Comments